Skip to main content
Top
Published in: Inflammation 1/2012

01-02-2012

Stimulation of FasL Induces Production of Proinflammatory Mediators Through Activation of Mitogen-Activated Protein Kinases and Nuclear Factor-κB in THP-1 Cells

Authors: Sang-Min Lee, Eun-Ju Kim, Kyoungho Suk, Won-Ha Lee

Published in: Inflammation | Issue 1/2012

Login to get access

Abstract

FasL is a member of the tumor necrosis factor (TNF) superfamily involved in the various immune reactions such as activation-induced cell death, cytotoxic effector function, and establishment of immune privileged sites through its interaction with Fas. On the other hand, FasL is known to transmit a reverse signal that serves as a T cell co-stimulatory signal. However, the role of FasL-mediated reverse signaling in macrophage function has not been investigated. In order to investigate the presence of FasL-mediated signaling in macrophages, the human macrophage-like cell line THP-1 was analyzed after treatment with FasL ligating agents such as recombinant Fas:Fc fusion protein or anti-FasL monoclonal antibody. Stimulation of FasL induced the expression of proinflammatory mediators such as matrix metalloproteinase-9, TNF-α, and IL-8. The specificity of the reaction was confirmed by the transfection of the FasL-specific siRNAs, which suppressed FasL expression as well as the production of proinflammatory mediators. Utilization of various inhibitors of signaling adaptors and ELISA-base nuclear factor (NF)-κB binding assay demonstrated that the signaling initiated from FasL is mediated by mitogen-activated protein kinases including extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase which induce subsequent activation of NF-κB. These data indicate that membrane expression of FasL and its interaction with its counterpart may contribute to the inflammatory activation of macrophages during immune reactions or pathogenesis of chronic inflammatory diseases.
Literature
1.
go back to reference Chen, N.J., M.W. Huang, and S.L. Hsieh. 2001. Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine. Journal of Immunology 166: 270–276. Chen, N.J., M.W. Huang, and S.L. Hsieh. 2001. Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine. Journal of Immunology 166: 270–276.
2.
go back to reference van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 378: 620–623.PubMedCrossRef van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 378: 620–623.PubMedCrossRef
3.
go back to reference Cerutti, A., A. Schaffer, R.G. Goodwin, S. Shah, H. Zan, S. Ely, and P. Casali. 2000. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD + IgM + B cells. Journal of Immunology 165: 786–794. Cerutti, A., A. Schaffer, R.G. Goodwin, S. Shah, H. Zan, S. Ely, and P. Casali. 2000. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD + IgM + B cells. Journal of Immunology 165: 786–794.
4.
go back to reference Zhang, J., T.W. Salcedo, X. Wan, S. Ullrich, B. Hu, T. Gregorio, P. Feng, S. Qi, H. Chen, Y.H. Cho, Y. Li, P.A. Moore, and J. Wu. 2001. Modulation of T-cell responses to alloantigens by TR6/DcR3. Journal of Clinical Investigation 107: 1459–1468.PubMedCrossRef Zhang, J., T.W. Salcedo, X. Wan, S. Ullrich, B. Hu, T. Gregorio, P. Feng, S. Qi, H. Chen, Y.H. Cho, Y. Li, P.A. Moore, and J. Wu. 2001. Modulation of T-cell responses to alloantigens by TR6/DcR3. Journal of Clinical Investigation 107: 1459–1468.PubMedCrossRef
5.
go back to reference Chou, A.H., H.F. Tsai, L.L. Lin, S.L. Hsieh, P.I. Hsu, and P.N. Hsu. 2001. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. Journal of Immunology 167: 1347–1352. Chou, A.H., H.F. Tsai, L.L. Lin, S.L. Hsieh, P.I. Hsu, and P.N. Hsu. 2001. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. Journal of Immunology 167: 1347–1352.
6.
go back to reference Suzuki, I., and P.J. Fink. 2000. The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America 97: 1707–1712.PubMedCrossRef Suzuki, I., and P.J. Fink. 2000. The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America 97: 1707–1712.PubMedCrossRef
7.
go back to reference Bae, E.M., W.J. Kim, K. Suk, Y.M. Kang, J.E. Park, W.Y. Kim, E.M. Choi, B.K. Choi, B.S. Kwon, and W.H. Lee. 2008. Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages. Molecular Immunology 45: 523–533.PubMedCrossRef Bae, E.M., W.J. Kim, K. Suk, Y.M. Kang, J.E. Park, W.Y. Kim, E.M. Choi, B.K. Choi, B.S. Kwon, and W.H. Lee. 2008. Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages. Molecular Immunology 45: 523–533.PubMedCrossRef
8.
go back to reference Jeon, S.T., W.J. Kim, S.M. Lee, M.Y. Lee, S.B. Park, S.H. Lee, I.S. Kim, K. Suk, B.K. Choi, E.M. Choi, B.S. Kwon, and W.H. Lee. 2010. Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunology and Cell Biology 88: 148–156.PubMedCrossRef Jeon, S.T., W.J. Kim, S.M. Lee, M.Y. Lee, S.B. Park, S.H. Lee, I.S. Kim, K. Suk, B.K. Choi, E.M. Choi, B.S. Kwon, and W.H. Lee. 2010. Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunology and Cell Biology 88: 148–156.PubMedCrossRef
9.
go back to reference Lee, S.M., S.T. Jeon, W.J. Kim, K. Suk, and W.H. Lee. 2010. Macrophages express membrane bound form of APRIL that can generate immunomodulatory signals. Immunology 131: 350–356.PubMedCrossRef Lee, S.M., S.T. Jeon, W.J. Kim, K. Suk, and W.H. Lee. 2010. Macrophages express membrane bound form of APRIL that can generate immunomodulatory signals. Immunology 131: 350–356.PubMedCrossRef
10.
go back to reference Lettau, M., M. Paulsen, D. Kabelitz, and O. Janssen. 2009. FasL expression and reverse signalling. Results and Problems in Cell Differentiation 49: 49–61.PubMedCrossRef Lettau, M., M. Paulsen, D. Kabelitz, and O. Janssen. 2009. FasL expression and reverse signalling. Results and Problems in Cell Differentiation 49: 49–61.PubMedCrossRef
11.
go back to reference Krammer, P.H., R. Arnold, and I.N. Lavrik. 2007. Life and death in peripheral T cells. Nature Reviews. Immunology 7: 532–542.PubMedCrossRef Krammer, P.H., R. Arnold, and I.N. Lavrik. 2007. Life and death in peripheral T cells. Nature Reviews. Immunology 7: 532–542.PubMedCrossRef
12.
go back to reference Brunner, T., C. Wasem, R. Torgler, I. Cima, S. Jakob, and N. Corazza. 2003. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Seminars in Immunology 15: 167–176.PubMedCrossRef Brunner, T., C. Wasem, R. Torgler, I. Cima, S. Jakob, and N. Corazza. 2003. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Seminars in Immunology 15: 167–176.PubMedCrossRef
13.
go back to reference Igney, F.H., and P.H. Krammer. 2005. Tumor counterattack: fact or fiction? Cancer Immunology, Immunotherapy 54: 1127–1136.PubMedCrossRef Igney, F.H., and P.H. Krammer. 2005. Tumor counterattack: fact or fiction? Cancer Immunology, Immunotherapy 54: 1127–1136.PubMedCrossRef
14.
go back to reference Niederkorn, J.Y. 2006. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nature Immunology 7: 354–359.PubMedCrossRef Niederkorn, J.Y. 2006. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nature Immunology 7: 354–359.PubMedCrossRef
15.
go back to reference Suzuki, I., and P.J. Fink. 1998. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. The Journal of Experimental Medicine 187: 123–128.PubMedCrossRef Suzuki, I., and P.J. Fink. 1998. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. The Journal of Experimental Medicine 187: 123–128.PubMedCrossRef
16.
go back to reference Suzuki, I., S. Martin, T.E. Boursalian, C. Beers, and P.J. Fink. 2000. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. Journal of Immunology 165: 5537–5543. Suzuki, I., S. Martin, T.E. Boursalian, C. Beers, and P.J. Fink. 2000. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. Journal of Immunology 165: 5537–5543.
17.
go back to reference Desbarats, J., R.C. Duke, and M.K. Newell. 1998. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Natural Medicines 4: 1377–1382.CrossRef Desbarats, J., R.C. Duke, and M.K. Newell. 1998. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Natural Medicines 4: 1377–1382.CrossRef
18.
go back to reference Sun, M., S. Lee, S. Karray, M. Levi-Strauss, K.T. Ames, and P.J. Fink. 2007. Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. Journal of Immunology 179: 5639–5643. Sun, M., S. Lee, S. Karray, M. Levi-Strauss, K.T. Ames, and P.J. Fink. 2007. Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. Journal of Immunology 179: 5639–5643.
19.
go back to reference Sun, M., K.T. Ames, I. Suzuki, and P.J. Fink. 2006. The cytoplasmic domain of Fas ligand costimulates TCR signals. Journal of Immunology 177: 1481–1491. Sun, M., K.T. Ames, I. Suzuki, and P.J. Fink. 2006. The cytoplasmic domain of Fas ligand costimulates TCR signals. Journal of Immunology 177: 1481–1491.
20.
go back to reference Sun, M., and P.J. Fink. 2007. A new class of reverse signaling costimulators belongs to the TNF family. Journal of Immunology 179: 4307–4312. Sun, M., and P.J. Fink. 2007. A new class of reverse signaling costimulators belongs to the TNF family. Journal of Immunology 179: 4307–4312.
21.
go back to reference Izawa, K., J. Kitaura, Y. Yamanishi, T. Matsuoka, A. Kaitani, M. Sugiuchi, M. Takahashi, A. Maehara, Y. Enomoto, T. Oki, T. Takai, and T. Kitamura. 2009. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. Journal of Immunology 183: 925–936.CrossRef Izawa, K., J. Kitaura, Y. Yamanishi, T. Matsuoka, A. Kaitani, M. Sugiuchi, M. Takahashi, A. Maehara, Y. Enomoto, T. Oki, T. Takai, and T. Kitamura. 2009. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. Journal of Immunology 183: 925–936.CrossRef
22.
go back to reference Lee, S.M., Y.P. Nam, K. Suk, and Lee WH. 2010. Immune receptor expressed on myeloid cells 1 (IREM-1) inhibits B cell activation factor (BAFF)-mediated inflammatory regulation of THP-1 cells through modulation of the activities of extracellular regulated kinase (ERK). Clinical & Experimental Immunology 161: 504–511.CrossRef Lee, S.M., Y.P. Nam, K. Suk, and Lee WH. 2010. Immune receptor expressed on myeloid cells 1 (IREM-1) inhibits B cell activation factor (BAFF)-mediated inflammatory regulation of THP-1 cells through modulation of the activities of extracellular regulated kinase (ERK). Clinical & Experimental Immunology 161: 504–511.CrossRef
23.
go back to reference Xi, H., K.J. Katschke Jr., K.Y. Helmy, P.A. Wark, N. Kljavin, H. Clark, J. Eastham-Anderson, T. Shek, M. Roose-Girma, N. Ghilardi, and M. van Lookeren Campagne. 2010. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. The Journal of Experimental Medicine 207(7–16): S1–S5. Xi, H., K.J. Katschke Jr., K.Y. Helmy, P.A. Wark, N. Kljavin, H. Clark, J. Eastham-Anderson, T. Shek, M. Roose-Girma, N. Ghilardi, and M. van Lookeren Campagne. 2010. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. The Journal of Experimental Medicine 207(7–16): S1–S5.
24.
go back to reference Chong, Z.Z., and K. Maiese. 2007. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histology and Histopathology 22: 1251–1267.PubMed Chong, Z.Z., and K. Maiese. 2007. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histology and Histopathology 22: 1251–1267.PubMed
25.
go back to reference Lorenz, U. 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunological Reviews 228: 342–359.PubMedCrossRef Lorenz, U. 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunological Reviews 228: 342–359.PubMedCrossRef
26.
go back to reference Bonny, C., A. Oberson, S. Negri, C. Sauser, and D.F. Schorderet. 2001. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50: 77–82.PubMedCrossRef Bonny, C., A. Oberson, S. Negri, C. Sauser, and D.F. Schorderet. 2001. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50: 77–82.PubMedCrossRef
27.
go back to reference Rosenau, C., D. Emery, B. Kaboord, and M.W. Qoronfleh. 2004. Development of a high-throughput plate-based chemiluminescent transcription factor assay. Journal of Biomolecular Screening 9: 334–342.PubMedCrossRef Rosenau, C., D. Emery, B. Kaboord, and M.W. Qoronfleh. 2004. Development of a high-throughput plate-based chemiluminescent transcription factor assay. Journal of Biomolecular Screening 9: 334–342.PubMedCrossRef
28.
go back to reference Lee, W.H., S.H. Kim, Y. Lee, B.B. Lee, B. Kwon, H. Song, B.S. Kwon, and J.E. Park. 2001. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology 21: 2004–2010.PubMedCrossRef Lee, W.H., S.H. Kim, Y. Lee, B.B. Lee, B. Kwon, H. Song, B.S. Kwon, and J.E. Park. 2001. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology 21: 2004–2010.PubMedCrossRef
29.
go back to reference Kim, W.J., and W.H. Lee. 2004. LIGHT is expressed in foam cells and involved in destabilization of atherosclerotic plaques through induction of matrix metalloproteinase-9 and IL-8. Immune Network 4: 116–122. Kim, W.J., and W.H. Lee. 2004. LIGHT is expressed in foam cells and involved in destabilization of atherosclerotic plaques through induction of matrix metalloproteinase-9 and IL-8. Immune Network 4: 116–122.
30.
go back to reference Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cellular Signalling 13: 85–94.PubMedCrossRef Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cellular Signalling 13: 85–94.PubMedCrossRef
31.
go back to reference Hu, X., L.C. Moscinski, N.I. Valkov, A.B. Fisher, B.J. Hill, and K.S. Zuckerman. 2000. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth & Differentiation 11: 191–200. Hu, X., L.C. Moscinski, N.I. Valkov, A.B. Fisher, B.J. Hill, and K.S. Zuckerman. 2000. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth & Differentiation 11: 191–200.
32.
go back to reference Requena, P., A. Daddaoua, E. Guadix, A. Zarzuelo, M.D. Suarez, F. Sanchez de Medina, and O. Martinez-Augustin. 2009. Bovine glycomacropeptide induces cytokine production in human monocytes through the stimulation of the MAPK and the NF-kappaB signal transduction pathways. British Journal of Pharmacology 157: 1232–1240.PubMedCrossRef Requena, P., A. Daddaoua, E. Guadix, A. Zarzuelo, M.D. Suarez, F. Sanchez de Medina, and O. Martinez-Augustin. 2009. Bovine glycomacropeptide induces cytokine production in human monocytes through the stimulation of the MAPK and the NF-kappaB signal transduction pathways. British Journal of Pharmacology 157: 1232–1240.PubMedCrossRef
33.
go back to reference Yang, Y., N. Lu, J. Zhou, Z.N. Chen, and P. Zhu. 2008. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 47: 1299–1310.CrossRef Yang, Y., N. Lu, J. Zhou, Z.N. Chen, and P. Zhu. 2008. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 47: 1299–1310.CrossRef
34.
go back to reference Ballif, B.A., A. Shimamura, E. Pae, and J. Blenis. 2001. Disruption of 3-phosphoinositide-dependent kinase 1 (PDK1) signaling by the anti-tumorigenic and anti-proliferative agent N-alpha-tosyl-l-phenylalanyl chloromethyl ketone. The Journal of Biological Chemistry 276: 12466–12475.PubMedCrossRef Ballif, B.A., A. Shimamura, E. Pae, and J. Blenis. 2001. Disruption of 3-phosphoinositide-dependent kinase 1 (PDK1) signaling by the anti-tumorigenic and anti-proliferative agent N-alpha-tosyl-l-phenylalanyl chloromethyl ketone. The Journal of Biological Chemistry 276: 12466–12475.PubMedCrossRef
35.
go back to reference Han, Y., J.A. Englert, R. Yang, R.L. Delude, and M.P. Fink. 2005. Ethyl pyruvate inhibits nuclear factor-κB-dependent signaling by directly targeting p65. The Journal of Pharmacology and Experimental Therapeutics 312: 1097–1105.PubMedCrossRef Han, Y., J.A. Englert, R. Yang, R.L. Delude, and M.P. Fink. 2005. Ethyl pyruvate inhibits nuclear factor-κB-dependent signaling by directly targeting p65. The Journal of Pharmacology and Experimental Therapeutics 312: 1097–1105.PubMedCrossRef
36.
go back to reference Wahl, C., S. Liptay, G. Adler, and R.M. Schmid. 1998. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. Journal of Clinical Investigation 101: 1163–1174.PubMedCrossRef Wahl, C., S. Liptay, G. Adler, and R.M. Schmid. 1998. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. Journal of Clinical Investigation 101: 1163–1174.PubMedCrossRef
37.
go back to reference Fenteany, G., and M. Glogauer. 2004. Cytoskeletal remodeling in leukocyte function. Current Opinion in Hematology 11: 15–24.PubMedCrossRef Fenteany, G., and M. Glogauer. 2004. Cytoskeletal remodeling in leukocyte function. Current Opinion in Hematology 11: 15–24.PubMedCrossRef
38.
go back to reference May, R.C., and L.M. Machesky. 2001. Phagocytosis and the actin cytoskeleton. Journal of Cell Science 114: 1061–1077.PubMed May, R.C., and L.M. Machesky. 2001. Phagocytosis and the actin cytoskeleton. Journal of Cell Science 114: 1061–1077.PubMed
39.
go back to reference Alvarez-Errico, D., H. Aguilar, F. Kitzig, T. Brckalo, J. Sayos, and M. Lopez-Botet. 2004. IREM-1 is a novel inhibitory receptor expressed by myeloid cells. European Journal of Immunology 34: 3690–3701.PubMedCrossRef Alvarez-Errico, D., H. Aguilar, F. Kitzig, T. Brckalo, J. Sayos, and M. Lopez-Botet. 2004. IREM-1 is a novel inhibitory receptor expressed by myeloid cells. European Journal of Immunology 34: 3690–3701.PubMedCrossRef
40.
go back to reference Sui, L., N. Li, Q. Liu, W. Zhang, T. Wan, B. Wang, K. Luo, H. Sun, and X. Cao. 2004. IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochemical and Biophysical Research Communications 319: 920–928.PubMedCrossRef Sui, L., N. Li, Q. Liu, W. Zhang, T. Wan, B. Wang, K. Luo, H. Sun, and X. Cao. 2004. IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochemical and Biophysical Research Communications 319: 920–928.PubMedCrossRef
41.
go back to reference Chung, D.H., M.B. Humphrey, M.C. Nakamura, D.G. Ginzinger, W.E. Seaman, and M.R. Daws. 2003. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. Journal of Immunology 171: 6541–6548. Chung, D.H., M.B. Humphrey, M.C. Nakamura, D.G. Ginzinger, W.E. Seaman, and M.R. Daws. 2003. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. Journal of Immunology 171: 6541–6548.
42.
go back to reference Alvarez-Errico, D., J. Sayos, and M. Lopez-Botet. 2007. The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. Journal of Immunology 178: 808–816. Alvarez-Errico, D., J. Sayos, and M. Lopez-Botet. 2007. The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. Journal of Immunology 178: 808–816.
Metadata
Title
Stimulation of FasL Induces Production of Proinflammatory Mediators Through Activation of Mitogen-Activated Protein Kinases and Nuclear Factor-κB in THP-1 Cells
Authors
Sang-Min Lee
Eun-Ju Kim
Kyoungho Suk
Won-Ha Lee
Publication date
01-02-2012
Publisher
Springer US
Published in
Inflammation / Issue 1/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9283-3

Other articles of this Issue 1/2012

Inflammation 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.